Brand Name for TDF/FTC
The brand name for the fixed-dose combination of tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) is Truvada. 1, 2
Key Information
The combination is marketed as Truvada® and contains:
- Tenofovir disoproxil fumarate 300 mg
- Emtricitabine 200 mg
This fixed-dose combination is administered orally once daily and is FDA-approved for two primary indications 2:
HIV Treatment
- Used as part of combination antiretroviral therapy for HIV-1 infection
- Widely incorporated into first-line treatment regimens 2
HIV Pre-Exposure Prophylaxis (PrEP)
- Approved for reducing the risk of sexually acquired HIV-1 in high-risk adults who are not infected 2
- Remains a recommended oral PrEP regimen for all populations likely to be exposed to HIV 3
Generic Availability
Generic formulations of tenofovir disoproxil fumarate/emtricitabine are now available and are equally recommended for PrEP use 3. The guidelines explicitly state that "daily oral TDF/FTC (including generic tenofovir disoproxil fumarate formulations) remains a recommended oral PrEP regimen for all populations likely to be exposed to HIV" 3.